Status:

RECRUITING

Transnasal Induction of Normothermia for Neurogenic Fever

Lead Sponsor:

CoolTech LLC

Collaborating Sponsors:

Maryland Industrial Partnerships

Conditions:

Stroke, Ischemic

Stroke Hemorrhagic

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusi...

Eligibility Criteria

Inclusion

  • Admitted to an Intensive Care Unit for a planned stay of at least 24 hours with a diagnosis of ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy.
  • Ages 18-85 years, inclusive.
  • Patient has fever ≥ 38.3°C and ≤ 38.9°C at the time of treatment initiation.
  • Patient is orally intubated or has tracheostomy tube and is mechanically ventilated.
  • Glasgow Coma Scale score of 3-11, inclusive.
  • Must have informed consent from the patient or the legally authorized representative (LAR) making decisions for the patient.

Exclusion

  • Intubation is contraindicated.
  • Weight of ≤ 100lb or ≥ 250lb.
  • Active/ongoing epistaxis.
  • Known or suspected pregnancy.
  • Participation in another ongoing investigational study.
  • Prisoners and/or patients for whom no LAR is available.
  • Patient is in airborne/droplet disease isolation protocol.
  • Patient is or suspected to be immunocompromised.
  • Nasal septal deviations (per standard of care CT scan; any degree).
  • Chronic rhinosinusitis.
  • Traumatic brain injury.
  • Prior skull-base surgery.
  • Penetrating cranial trauma.
  • Recent nasal trauma or anterior base skull fracture.
  • Any condition for which transnasal air flow would be contraindicated.
  • Refractory hypoxemia (partial pressure of oxygen in arterial blood (paO2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60).
  • Refractory hypercarbia (partial pressure of carbon dioxide in arterial blood (paCO2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation).

Key Trial Info

Start Date :

November 21 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2025

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT06038513

Start Date

November 21 2023

End Date

October 1 2025

Last Update

February 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Maryland Medical Center

Baltimore, Maryland, United States, 21201